Pinitol (D-Pinitol / 3-O-Methyl-d-chiro-inositol): A Comprehensive Reference
1. Identity, Chemistry, and Physical Character
D-Pinitol (formally 3-O-methyl-d-chiro-inositol) is a cyclitol nearly ubiquitous in the Leguminosae and Pinaceae plant families. The compound belongs to the broader chemical class of inositols — cyclic polyols that are six-membered carbocyclic rings carrying hydroxyl groups on each carbon. More specifically, pinitol is a cyclic polyol derived from the methylation of myo-inositol (an isomer of inositol) and plays an important role as a protective and signaling compound. The methyl ether group is positioned at carbon-3 of the chiro-inositol ring, a structural fact that has sometimes been misrepresented in older literature; one earlier reference incorrectly identifies pinitol as an ester rather than an ether of D-chiro-inositol.
The biosynthesis of D-pinitol in plants proceeds from the common precursor myo-inositol. Pinitol is synthesised from myo-inositol by the sequential action of two enzymes: inositol-O-methyltransferase (IMT1) and ononitol epimerase (OEP1). The first enzyme installs the methyl group onto myo-inositol to form ononitol (4-O-methyl-myo-inositol), and the second enzyme then epimerises ononitol to yield D-pinitol. The molecular formula is C7H14O6 and the compound presents as a white crystalline solid that is freely soluble in water.
Among the several inositols studied for their potential use against insulin resistance, D-Pinitol (DPIN, 3-O-methyl-d-chiro-inositol) is considered a potential dietary source of D-chiro-inositol (DCI) since it can be demethylated in the acid media of the stomach. This metabolic relationship means that a portion of orally consumed D-pinitol may exert effects attributed to both the parent compound and its demethylated product DCI.
Suitable derivatives and metabolites of pinitol include pinitol glycosides, pinitol phospholipids, esterified pinitol, lipid-bound pinitol, pinitol phosphates, and pinitol phytates.
2. Natural Sources and Botanical Distribution
D-Pinitol is a cyclitol nearly ubiquitous in the Leguminosae and Pinaceae families, playing an important role in plants as a physiological cellular modulator and chemical defense against unfavorable environmental conditions, such as water deficit and high levels of salinity. Its accumulation in plants under osmotic and salt stress is a characteristic adaptive response that facilitates cellular osmotic adjustment.
Major dietary and commercial plant sources include:
- Legumes: Familiar plants contain large amounts of inositols; soybean, white clover, red clover, bush clover, locust tree, wisteria, and kudzu of the legume family contain pinitol (3-O-methyl-chiro-inositol) at approximately 200–600 mg per 100 g fresh weight.
- Carob (Ceratonia siliqua L.): D-Pinitol is a naturally occurring inositol found in many plant species, and carob has the highest content of D-Pinitol. Although many synthetic and semi-synthetic methods have been reported for D-pinitol, Ceratonia siliqua L. (Carob) is the only raw material from which D-pinitol can be isolated in quantities sufficient for viable commercial exploitation.
- Bougainvillea (Bougainvillea spectabilis): Carob pod, Bougainvillea, soy whey, and soybean oligosaccharides were identified as rich sources of chiro-inositol (including pinitol).
- Pine needles and pine wood: Pinitol and its derivatives are available from a number of natural sources, such as pine needles, chick peas, Bougainvillea leaves, alfalfa, soybeans, and other legumes, but are preferably obtained from soy fractions.
- Other plants: The contents of pinitol in other plants were 260 mg per 100 g fresh weight for sticky mouse-ear, 275 mg per 100 g fresh weight for chickweed, and 332 mg per 100 g fresh weight for ginkgo.
For commercial isolation and manufacturing, pinitol has been isolated from soy whey and carob pod, considered as economically viable sources, by chromatographic separation using activated carbon. Soy- and carob-derived pinitols have been confirmed to have the same chemical structure as reference pinitol based on HPLC and NMR results.
3. Traditional and Historical Use
The historical use of pinitol as an isolated compound is essentially a modern phenomenon tied to its identification as an active constituent of traditional medicinal plants. What traditional cultures employed were the whole plants containing pinitol, often without knowledge of the specific molecule responsible for therapeutic activity.
Plants rich in D-pinitol are being used in traditional medicine as empirical treatment for diabetes, inflammation, cancer, or infections.
Ayurvedic Medicine (Indian subcontinent): Pinitol is a component of traditional Ayurvedic medicine where it serves as the active constituent of talisapatra, a preparation that has been shown to exhibit anti-inflammatory and antidiabetic activities. D-Pinitol can be found and isolated from many plants, being the active component of Ayurvedic remedies such as Talisa patra (Abies webbiana, A. pindrow), and is the antidiabetic active component of Bougainvillea (Bougainvillea spectabilis). Preparations derived from these plants have been used classically for managing symptoms consistent with diabetes mellitus and inflammatory conditions. Bougainvillea leaf decoctions were specifically employed in Indian folk medicine for blood sugar management.
Mediterranean traditional use (Carob): Carob (Ceratonia siliqua) is one of the major food trees for peoples of the Mediterranean basin, and it has also been traditionally used for medicinal purposes. The fruit pods of carob have a centuries-long history as a food stabiliser, a treatment for gastrointestinal complaints, and a general tonic in communities throughout the Levant, North Africa, and Southern Europe. Modern analysis has since identified D-pinitol as one of the primary bioactive constituents responsible for the metabolic properties attributed to these preparations.
South African traditional medicine: Several South African medicinal plants used traditionally for the management of diabetes have been found to contain pinitol, and researchers have noted that the presence of pinitol in these plants helps explain their traditional antidiabetic applications.
Legume food traditions: Populations with high dietary legume intake — including chickpeas, soybeans, alfalfa, and various clovers — have consumed meaningful quantities of pinitol through diet without medicinal intent. A serving containing over 100 grams (approximately one quarter pound) of soy per day, which is a reasonable portion for some individuals, would provide about 1 gram of pinitol, or a dose level of over 10 mg/kg in a 70 kg individual.
4. Key Active Constituents and Established Mechanisms of Action
4.1 Identity as an Insulin Mimetic
Pinitol and D-chiro-inositol exert an insulin-like effect by mediating the post-receptor signaling pathway. This property — referred to as insulin mimetic or insulinomimetic activity — underpins the majority of pinitol's pharmacological effects, from glucose regulation to broader metabolic and anti-inflammatory actions.
D-Pinitol can be incorporated into inositol phosphoglycans (IPG), serving as INS-2, the insulin's second messenger, thus having similar effects on insulin signaling as IPG containing D-pinitol. This incorporation into second-messenger systems is considered a central mechanism by which D-pinitol amplifies and mimics insulin signaling downstream of the insulin receptor.
4.2 The PI3K/Akt Signaling Pathway
The most extensively characterised molecular mechanism of D-pinitol involves the phosphatidylinositol-3-kinase / protein kinase B (PI3K/Akt) cascade, a central node in the insulin signaling pathway responsible for glucose uptake. Western blot analysis in diabetic rats demonstrated that D-pinitol promotes the expression of phosphatidylinositol-3-kinase (PI3K) p85 and PI3K p110, as well as the downstream target protein kinase B/Akt (at Ser473). D-pinitol also inhibited the expression of glycogen synthase kinase-3β (GSK-3β) protein and regulated the expression of glycogen synthase (GS) protein, thereby accelerating glycogen synthesis, and played a positive role in regulating insulin-mediated glucose uptake in the liver through translocation and activation of the PI3K/Akt signaling pathway.
Pinitol also increased GLUT4 and IRS gene expression, perhaps due to its insulin-mimicking property, and the blood glucose-lowering property of pinitol is mediated via the insulin signaling pathway. GLUT4 is the primary insulin-responsive glucose transporter responsible for clearing glucose from the bloodstream into skeletal muscle and adipose tissue.
Research in rat hypothalamic tissue demonstrated that the PI3K/Akt pathway is not confined to peripheral metabolic tissues. Acute administration of D-Pinitol induced time-dependent phosphorylation of PI3K/Akt and its related substrates within the hypothalamus, indicating an activation of the insulin signaling pathway; D-Pinitol is a naturally occurring inositol capable of activating the insulin pathway in peripheral tissues. These findings suggest that D-Pinitol might be a candidate to treat brain insulin-resistance associated disorders by activating insulin response beyond the insulin receptor.
4.3 Suppression of NF-κB Activation
Pinitol (3-O-methyl-chiroinositol), a component of traditional Ayurvedic medicine, has been shown to exhibit anti-inflammatory and antidiabetic activities; because the transcription factor nuclear factor-κB (NF-κB) has been linked with inflammatory diseases including insulin resistance, pinitol mediates its effects through modulation of NF-κB activation, suppressing NF-κB activation induced by inflammatory stimuli and carcinogens. Pinitol also abrogated constitutive NF-κB activation noted in most tumor cells. The suppression of NF-κB activation by pinitol occurred through inhibition of the activation of IκBα kinase, leading to sequential suppression of IκBα phosphorylation, IκBα degradation, p65 phosphorylation, p65 nuclear translocation, and NF-κB-dependent reporter gene expression. This mechanism is the likely common ground linking pinitol's anti-inflammatory and potential anticancer properties.
4.4 Antioxidant and Hepatoprotective Mechanisms
D-pinitol has demonstrated potential hepatoprotective effects through its ability to reduce the activity of liver enzymes associated with hypercholesterolemia and fat accumulation, including HMG-CoA reductase (HMGR), acyl-CoA-cholesterol acyltransferase (ACAT), and cytochrome P4502E1 (CYP2E1). In animal models, oral administration of D-pinitol to streptozotocin-induced diabetic rats for 30 days significantly decreased the levels of lipid peroxides and hydroperoxides and increased the activities of enzymatic antioxidants, including superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), and glutathione S-transferase (GST).
5. Scientific Evidence by Area of Use
5.1 Glycemic Control and Type 2 Diabetes Mellitus
Overview: The most substantial body of clinical research on pinitol concerns its effects on blood glucose regulation and insulin sensitivity in persons with type 2 diabetes (T2DM) or impaired glucose tolerance. The evidence is mixed, with some randomised controlled trials (RCTs) showing benefit and others showing no effect, with important differences in study design, population, and dosing.
Key supportive RCT (Kim et al., 2012): Researchers evaluated the effects of pinitol on glycemic control, insulin resistance and adipocytokine levels in type 2 diabetic patients; a total of 66 patients with type 2 diabetes who had been taking oral hypoglycemic agents for at least 3 months were enrolled and randomized to receive pinitol (n = 33) or matching placebo (n = 33), with all subjects taking 1,200 mg pinitol or placebo while maintaining their current oral hypoglycemic agents throughout the study. Mean HbA1c, fasting plasma glucose, and HOMA-IR were significantly lowered more in patients taking pinitol than in those given a placebo. Patients who had an HbA1c over 8.0% showed a greater reduction (p < 0.01) than those who had an HbA1c below 8.0%, suggesting a population-dependent magnitude of benefit. The conclusion drawn was that pinitol can mediate insulin action to improve glycemic control and insulin sensitivity in patients with type 2 diabetes mellitus, especially in patients with insulin resistance.
Neutral RCT (Davis et al., 2000): An earlier and methodologically different trial enrolled a smaller and distinct population. Researchers tested the hypothesis that oral administration of soybean-derived pinitol would improve insulin sensitivity in obese subjects (BMI = 36.6 kg/m²) with diet-treated type 2 diabetes or glucose intolerance (HbA1c = 6.8%); 22 subjects were randomized to receive either pinitol 20 mg·kg⁻¹·day⁻¹ (n = 12) or placebo (n = 10) in a 28-day double-blinded trial. Four weeks of pinitol treatment did not alter baseline glucose production, insulin-mediated glucose disposal, or rates of appearance of free fatty acids and glycerol in plasma; the authors concluded that plasma levels of both pinitol and D-chiro-inositol are very responsive to pinitol ingestion, but insulin sensitivity does not increase after pinitol treatment in individuals with obesity and mild type 2 diabetes. The authors suggested that these obese, diabetic, and impaired glucose patients might have been resistant to the effects of pinitol because of inherent abnormalities in the insulin-signaling pathway.
Neutral RCT in older, non-diabetic adults: Limited research with rodents and humans suggests that oral ingestion of pinitol might positively influence glucose tolerance. A double-blind, placebo-controlled crossover study in older, non-diabetic humans found a different result: these results show that the pinitol supplement was quickly absorbed, but did not acutely influence indices of whole-body glucose tolerance and insulin sensitivity, or the activation of the skeletal muscle insulin receptor in older, nondiabetic humans.
Animal (preclinical) evidence: In a model of type 2 diabetes established by feeding a high-fat diet and injecting streptozotocin in Sprague-Dawley rats, D-pinitol was administered at two doses (30 and 60 mg per kg body weight per day); the level of fasting blood glucose was decreased by 12.63% in the high-dosage group and oral glucose tolerance was improved in D-pinitol-treated groups.
Overall strength of evidence: Preliminary to moderate. Results in clinical populations are inconsistent. The most positive trial (Kim et al., 2012) was conducted in a population already on pharmacological treatment for T2DM. Null results were observed in mild T2DM/obesity and in non-diabetic older adults. Larger, well-powered trials with pre-specified populations are needed before firm conclusions can be drawn.
5.2 Non-Alcoholic Fatty Liver Disease (NAFLD)
A double-blind, placebo-controlled, randomized clinical trial (RCT) was performed to evaluate the effects of two different doses of pinitol in 90 patients with NAFLD who were not taking medications and dietary supplements. The trial examined markers of liver health, oxidative stress, and metabolic function. In this one included RCT, pinitol supplementation obtained results showing that pinitol significantly reduced liver fat, post-prandial triglycerides, AST levels, and lipid peroxidation, while also increasing glutathione peroxidase activity. The results were satisfactory, and a higher dose of pinitol (500 mg) conferred an additional benefit over a low dose (300 mg) through further lowering of ALT and GGT.
In previous preclinical studies, pinitol has been suggested to possess multifunctional properties, including anti-hyperlipidemic and anti-inflammatory activities. Animal model data support the human trial findings: liver histopathology showed diminished lipid accumulation in pinitol-treated hamsters, whereas the untreated group developed a fatty liver with significantly larger adipocytes; likewise, pinitol normalized liver ultrastructure changes caused by streptozotocin-induced diabetes in rats.
These results, despite being limited, indicate the need for further evaluation of inositols including pinitol in NAFLD in larger clinical trials.
Overall strength of evidence: Preliminary. One RCT (90 subjects) with positive outcomes; supported by consistent animal data. Insufficient to support definitive efficacy claims without replication in larger trials.
5.3 Anti-Inflammatory Activity
The anti-inflammatory properties of pinitol have been characterised primarily through in vitro cell studies and animal models rather than dedicated human clinical trials targeting inflammation as the primary endpoint. Pinitol suppressed NF-κB activation induced by inflammatory stimuli and carcinogens, and this suppression was not specific to cell type; pinitol also abrogated constitutive NF-κB activation noted in most tumor cells. NF-κB is a master regulator of the inflammatory response, controlling the transcription of cytokines such as TNF-α, IL-1β, and IL-6.
Inositol improves liver function by lowering the levels of certain serum aminotransferases, such as aspartate aminotransferase (AST) and alanine aminotransferase (ALT), as well as that of the inflammatory cytokine tumor necrosis factor-alpha.
Overall strength of evidence: Preclinical only for inflammation-specific endpoints. Mechanistic data from cell and animal models are compelling, but no dedicated human RCTs have assessed pinitol as an anti-inflammatory agent with inflammation biomarkers as primary outcomes.
5.4 Anticancer Research
Anticancer investigations of pinitol have been conducted at the level of cell biology and animal models. The primary mechanism appears to involve NF-κB suppression. Pinitol abrogated constitutive NF-κB activation noted in most tumor cells, and this suppression occurred through inhibition of IκBα kinase activation, leading to sequential suppression of IκBα phosphorylation, IκBα degradation, p65 phosphorylation, p65 nuclear translocation, and NF-κB-dependent reporter gene expression. NF-κB-driven gene products involved in proliferation, apoptosis resistance, invasion, and angiogenesis were all reported to be affected in laboratory settings.
Many publications have reported activities of D-Pinitol as an active anticancer agent in addition to its antidiabetic and anti-inflammatory properties. However, all anticancer evidence for pinitol as of available literature comes from in vitro or animal experiments. No human clinical trials have been conducted to evaluate pinitol as a cancer treatment or preventive agent.
Overall strength of evidence: Preclinical only. In vitro and animal data provide mechanistic rationale, but no clinical evidence in humans exists. No clinical conclusions can be drawn.
5.5 Sports Performance and Creatine Co-ingestion
The use of pinitol in sports nutrition has been explored primarily in the context of its potential to enhance creatine uptake into muscle, leveraging its insulin-mimetic properties. Co-ingestion of D-pinitol with creatine (CR) has been reported to enhance creatine uptake. Investigations by Greenwood and colleagues reported increased creatine retention from the addition of low levels of D-pinitol, a plant extract with insulin-like properties.
A specific RCT addressed whether this reported augmentation of creatine uptake translates into greater functional and physical adaptations. The study evaluated whether adding D-pinitol to creatine affects training adaptations, body composition, whole-body creatine retention, and blood safety markers when compared to creatine ingestion alone after 4 weeks of resistance training; twenty-four resistance-trained males were randomly assigned in a double-blind manner to creatine + pinitol or creatine monohydrate prior to beginning a supervised 4-week resistance training program, and subjects ingested a loading phase of 20 g per day for 5 days before ingesting 5 g per day for the remaining 23 days. Creatine retention increased in both groups as a result of supplementation but was not different between groups; significant improvements in upper- and lower-body strength and body composition occurred in both groups, but significantly greater increases in lean mass and fat-free mass occurred in the creatine-alone group when compared to the creatine plus pinitol group; adding D-pinitol to creatine monohydrate does not appear to facilitate further physiological adaptations while resistance training.
The ISSN position on creatine notes that while the addition of D-pinitol to creatine has proven to increase muscle retention in some reports, several recent investigations have reported these combinations to be no more effective at improving muscle strength and endurance or athletic performance.
Overall strength of evidence: Weak for performance outcomes. While short-term creatine retention increases have been noted, RCT evidence does not demonstrate additional performance or body-composition benefit from co-ingestion versus creatine alone.
5.6 Neurological and Hypothalamic Insulin Signaling
An emerging area of research examines whether pinitol's insulin-mimetic properties extend to the central nervous system. D-Pinitol is a naturally occurring inositol capable of activating the insulin pathway in peripheral tissues, and researchers have assessed its potential regulatory effects on the hypothalamic insulin signaling pathway. Preclinical animal work demonstrates that acute administration of D-Pinitol induced time-dependent phosphorylation of PI3K/Akt and its related substrates within the hypothalamus, indicating an activation of the insulin signaling pathway; this profile is consistent with D-Pinitol as an insulin sensitizer since a decrease in circulating insulin concentration was also found. These findings from rat models suggest that D-Pinitol might be a candidate to treat brain insulin-resistance associated disorders by activating insulin response beyond the insulin receptor.
Overall strength of evidence: Exclusively preclinical (animal models). No human clinical data address neurological endpoints. This area remains speculative and requires human investigation.
6. Body Systems and Health Areas Associated with Pinitol
- Endocrine / Metabolic system: Glucose homeostasis, insulin sensitivity, and adipocytokine regulation in the context of type 2 diabetes mellitus and insulin resistance.
- Hepatic system: Liver fat reduction, modulation of liver enzymes (AST, ALT, GGT), antioxidant enzyme induction (GPx, SOD, CAT), and protection against hepatocyte injury in NAFLD and experimentally induced hepatotoxicity.
- Inflammatory and immune system: Suppression of NF-κB-mediated transcription and reduction of pro-inflammatory cytokines including TNF-α.
- Musculoskeletal system: Investigated (with mixed results) as an adjunct to creatine supplementation for muscle creatine retention and body composition.
- Central nervous system: Hypothalamic insulin signaling activation in preclinical models; no human clinical data.
- Oncology (preclinical): Inhibition of NF-κB-dependent gene products associated with tumor cell proliferation, survival, invasion, and angiogenesis in cell culture and animal experiments only.
7. Pharmacokinetics in Humans
The pharmacokinetic profile of D-pinitol was characterised in a study of 25 healthy volunteers. The study characterises the oral pharmacokinetics of D-Pinitol in human healthy volunteers (14 males and 11 females), examining absorption from (a) a single oral dose of 15 mg/kg (n = 10), (b) 5 mg/kg pure D-Pinitol (n = 6), and (c) D-Pinitol as part of carbohydrate-containing carob pod-derived syrup with 3.2% D-Pinitol (dose of 1,600 mg per subject, n = 9).
The data indicate that when given alone, the oral absorption of D-Pinitol is dose-dependent and of extended duration, with a Tmax reached after almost 4 hours and a half-life greater than 5 hours. When the source of D-Pinitol was a carob pod-derived syrup, Cmax was reduced to 40% of the expected based on data from D-Pinitol alone, suggesting reduced absorption probably because of competition with monosaccharide transport; in this group, Tmax was reached earlier than with D-Pinitol alone, but the estimated half-life remained the same.
The implication for practitioners and researchers is that the co-ingestion of D-pinitol with carbohydrate-rich foods or beverages may substantially reduce its bioavailability. Supplemental pinitol administered in a fasted state achieves meaningfully higher plasma concentrations.
8. Dosage Forms and Doses Reported in Research Studies
The following dosages are drawn directly from the human clinical studies cited above. They are presented as reported in the literature and should not be interpreted as recommendations.
- In the Korean RCT in type 2 diabetic patients (n = 66), the dose used was 1,200 mg per day (as pinitol powder capsules), maintained alongside existing oral hypoglycemic medications.
- In the 28-day double-blind RCT in obese insulin-resistant subjects, the dose was 20 mg per kg per day (approximately 1,400 mg per day in a 70 kg individual) of soybean-derived pinitol.
- In the NAFLD clinical trial, two doses were compared: 300 mg per day and 500 mg per day, with the higher dose producing additional reductions in ALT and GGT.
- In the pharmacokinetic study in healthy volunteers, doses of 5 mg/kg and 15 mg/kg (pure D-pinitol), and a fixed carob syrup dose of 1,600 mg per subject, were studied.
- In the resistance training/creatine co-ingestion RCT, pinitol was co-administered with a creatine loading phase of 20 g per day for 5 days, followed by 5 g per day for 23 days; the exact dose of D-pinitol co-ingested was not independently specified in the abstract but was part of a commercial formulation.
- Animal study doses (for context only): D-pinitol was administered to diabetic rats as two doses of 30 or 60 mg per kg body weight per day.
9. Safety Considerations
In the 28-day double-blind human trial using doses of 20 mg per kg per day, no toxicity due to pinitol was observed during the study. By history of use, animal, and human clinical scientific studies, D-pinitol is considered non-toxic and safe in humans. Pinitol's long history as an endogenous dietary constituent of soybean and carob foods — consumed by broad populations over many centuries — contributes to its general safety profile.
Although findings in animal and in vitro studies are promising, most evidence comes from in vitro or animal studies, and additional research is needed to clarify the precise mechanisms in humans. This applies equally to the safety profile over long-term exposure, which has not been evaluated systematically in large-scale human studies.
9.1 Drug Interactions: Antidiabetic Medications
Because D-pinitol acts as an insulin mimetic and augments the PI3K/Akt insulin signaling cascade, additive glucose-lowering effects are plausible when it is co-administered with insulin, sulfonylureas, or other hypoglycemic drugs. The main clinical trial showing glycemic benefit enrolled patients who were already on oral hypoglycemic agents; all subjects maintained their current oral hypoglycemic agents throughout the study. This design does not permit isolation of pinitol's independent hypoglycemic effect from potential additive interactions with existing medications. Persons on blood-glucose-lowering medications who supplement with pinitol should be aware of this potential.
9.2 Reduced Bioavailability with Carbohydrate Co-ingestion
When the source of D-Pinitol was a carob pod-derived syrup, Cmax was reduced to 40% of the expected based on data from D-Pinitol alone, suggesting reduced absorption probably because of competition with monosaccharide transport. This represents a pharmacokinetic interaction between pinitol and dietary carbohydrates that could alter the expected dose–response relationship when pinitol is consumed with meals.
9.3 Commercial and Supplement Forms
Pinitol is a naturally occurring compound found in pine wood, alfalfa, and legumes, but is generally derived from soy or carob for manufacturing purposes. Supplement preparations include standardised powders, capsules, and tablets. It is also incorporated into proprietary creatine formulations marketed to athletes. Persons with soy allergies should verify the source of any commercial pinitol supplement.
10. Regulatory and Nomenclature Notes
D-Pinitol is not currently approved as a drug by any major regulatory authority (FDA, EMA). It is sold as a dietary supplement ingredient in numerous jurisdictions. It is not included in major official pharmacopoeial monographs such as the United States Pharmacopeia (USP) or the European Pharmacopoeia as a standalone entity, though inositol and its derivatives appear in various food and supplement regulatory frameworks. No official recommended daily intake has been established by the NIH, WHO, or EFSA for pinitol specifically.
References
Go back